Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency
Open Access
- 16 January 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 15 (3), 309-321
- https://doi.org/10.1093/humupd/dmn065
Abstract
Recombinant DNA technologies have been used to develop longer-acting therapeutic proteins. One approach is to introduce sequences containing additional glycosylation sites. Using this technique, a new chimeric gene has been developed containing the coding sequences of the FSH β-subunit and the C-terminal peptide of the hCG β-subunit, which bears four O-linked oligosaccharide binding sites. Co-expression of the α-subunit and the chimeric FSH β-subunit produces a new recombinant molecule, named corifollitropin alfa, with a prolonged elimination half-life and enhanced in vivo bioactivity compared with wild-type FSH. Medline searches by subject and additional searching by hand. Initial studies in pituitary suppressed female volunteers confirmed the extended half-life of the compound. Phase II studies have shown that corifollitropin alfa is able to induce and sustain multi-follicular growth for an entire week in women undergoing ovarian stimulation using GnRH antagonist co-treatment for IVF. Corifollitropin alfa regimens have been developed with dosages of 100 and 150 µg, for patients with body weight ≤60 and >60 kg, respectively. Corifollitropin alfa is the first long-acting hybrid molecule with sustained follicle-stimulating activity developed for the induction of multi-follicular growth along with GnRH antagonist co-treatment for IVF. This new treatment option may be simpler and more convenient for patients compared with conventional long protocols of daily FSH injections in combination with GnRH agonist co-treatment. The safety and efficacy of such regimens is currently being evaluated in large comparative phase III clinical trials. The development of corifollitropin alfa is the first step towards a new generation of recombinant gonadotrophins.Keywords
This publication has 92 references indexed in Scilit:
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Long-Acting Injectable Risperidone for the Treatment of SchizophreniaDrugs, 2007
- Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?Fertility and Sterility, 2005
- Historical perspectives in gonadotrophin therapyHuman Reproduction Update, 2004
- A comparison of 3-day and daily follicle-stimulating hormone injections on stimulation days 1–6 in women undergoing controlled ovarian hyperstimulationFertility and Sterility, 2004
- Expression of Biologically Active Fusion Genes Encoding the Common α Subunit and the Follicle-stimulating Hormone β SubunitJournal of Biological Chemistry, 1996
- Converting heterodimeric gonadotropins to genetically linked single chains: New approaches to structure activity relationships and analogue designTrends in Endocrinology & Metabolism, 1996
- Heterogeneity of follicle stimulating hormone: control and physiological functionHuman Reproduction Update, 1995
- Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiencyJournal of Clinical Endocrinology & Metabolism, 1992
- A model for follicular selection and ovulation: Lessons from superovulationJournal of Steroid Biochemistry, 1987